bt-11
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 6, 2018 (NCT03860571)
Timeline
Indications
Mechanism of action
- LanC-like protein 2INHIBITOR
LANCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04835168 | Phase 1 | Jan 30, 2022 | Landos Biopharma Inc. |
| NCT05057273 | Phase 2 | Nov 30, 2021 | Landos Biopharma Inc. |
| NCT03861143 | Phase 2 | Mar 31, 2019 | Landos Biopharma Inc. |
| NCT03870334 | Phase 2 | Mar 31, 2019 | Landos Biopharma Inc. |
| NCT03860571 | Phase 1 | Jul 6, 2018 | Landos Biopharma Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Landos Biopharma Inc. | For profit | 5 | 5 | 2 | 2018 |
1 organizations
Page 1 / 1